ANALYSIS OF CD10 EXPRESSION IN PROSTATE ADENOCARCINOMA AND ITS CORRELATION WITH DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AT RNTMC, UDAIPUR

NAVED KHAN; NAMITA GOYAL; ABHILASHA

doi:10.22159/ajpcr.2024v17i10.51974

Authors

NAVED KHAN Department of Pathology, RNTMC, Udaipur, Rajasthan, India.
NAMITA GOYAL Department of Pathology, RNTMC, Udaipur, Rajasthan, India.
ABHILASHA Department of Pathology, RNTMC, Udaipur, Rajasthan, India.

DOI:

https://doi.org/10.22159/ajpcr.2024v17i10.51974

Keywords:

CD10 prostate, adenocarcinoma, Gleason score, WHO

Abstract

Objective: The study aimed to analyze the expression of CD10 in prostate adenocarcinoma to aid in early diagnosis and anti-CD10 targeted therapy.

Methods: This was a cross-sectional study conducted in the Histopathology section of the Department of Pathologyat RNTMC, Udaipur, after approval from the ethical committee and institutional review board. This study was conducted on 92 patients suspected to have prostate cancer. The cases were assessed for Gleason score, Gleason Grade, and Serum Prostate Specific Antigen (PSA) levels. We performed IHC detection of CD10 in prostatic specimens and correlated the various patterns of CD10 expression concerning histopathological diagnosis.

Results: In our study, we found membranous expression in low-grade carcinomas with low Gleason score and grade. The high-grade carcinomas with high Gleason score and Grade predominantly showed cytoplasmic expression. The increased CD10 cytoplasmic expression was correlated with serum PSA level.

Conclusion: In our study, CD10 was found to be relevant. The low-grade carcinomas showed membranous positivity and high-grade carcinomas showed cytoplasmic expression. One hypothesis states that cytoplasmic expression is due to the localization of CD10 in the cytoplasm. Our study favors this hypothesis as there is cytoplasmic expression in high-grade tumors. In the future, this could be used as a diagnostic marker.

Downloads

Download data is not yet available.

References

Singh L, Marwah N, Bhutani N, Pawar D, Kapil R, Sen R. Study the expression of CD10 in prostate carcinoma and its correlation with various clinicopathological parameters. Iran J Pathol. 2019;14(2):135-45. doi: 10.30699/IJP.14.2.135, PMID: 31528170

Saranya D. Analysis of immunohistochemical expression of CD10 in the malignant lesions of prostate. IOSR J Dent Med Sci. 2017;16:78-82.

Fleischmann A, Schlomm T, Huland H, Köllermann J, Simon P, Mirlacher M, et al. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res. 2008 Dec 1;14(23):7838-42. doi: 10.1158/1078-0432.CCR-08-1432, PMID: 19047112

Dall’Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007 Dec;7(1):3.

Kaur M, Verma S, Gupta R, Pant L, Singh S. CD10 expression pattern in prostatic adenocarcinoma: Elucidation of differences between Gleason’s grades. Malays J Pathol. 2018 Apr 1;40(1):57-60. PMID: 29704385

Gülhan Ö, Mahi B. The role of AMACR, CD10, TMPRSS2-ERG, and p27 protein expression among different Gleason grades of prostatic adenocarcinoma on needle biopsy. Clin Med Insights Oncol. 2020 Aug;14;4:1-8. doi: 10.1177/1179554920947322, PMID: 35185351

Ghasemi A, Jalali Nadoushan M, Sedaghat R. Evaluation of CD10 Expression and its relationship with Gleason score in prostatic adenocarcinoma. J Babol Univ Med Sci. 2021 Mar 10;23(1):60-4.

Tawfic S, Niehans GA, Manivel JC. The pattern of CD10 expression in selected pathologic entities of the prostate gland. Hum Pathol. 2003 May 1;34(5):450-6. doi: 10.1016/s0046-8177(03)00077-7, PMID: 12792918

Erbersdobler A, Fritz H, Schnöger S, Graefen M, Hammerer P, Huland H, et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: Differences between tumours located in the transition zone and in the peripheral zone. Eur Urol. 2002 Jan 1;41(1):40- 6. doi: 10.1016/s0302-2838(01)00021-5, PMID: 11999464

Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6579-84. doi: 10.1158/1078- 0432.CCR-07-1257, PMID: 18006757